Login to Your Account



Earnings Roundup


Friday, February 25, 2011
Onyx Pharmaceuticals Inc., of Emeryville, Calif., reported that full-year net global sales of Nexavar grew 11 percent in 2010 to $934 million, and increased 9 percent in the fourth quarter to $257.4 million, compared to the same periods in 2009. Onyx and Bayer market and develop Nexavar (sorafenib) tablets, an anticancer therapy for the treatment of unresectable liver cancer and advanced kidney cancer, in more than 100 countries.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription